At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 173 enrolled
Drug / intervention
Ketorolac tromethamine +1 moredrug
Likely dose
Ketorolac tromethamine 31.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Analgesic Efficacy of Ketorolac Tromethamine Administered Intranasally for the Acute Treatment of Migraine
In Brief
A Phase 2 clinical trial evaluating Ketorolac tromethamine and Placebo for Migraine. Completed, enrolled 173 participants across 1 site.
Detailed Summary
The study evaluates the efficacy and safety of using ketorolac as a nasal spray for the acute treatment of migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2007
Enrollment StartJul 2007
Primary CompletionJan 2008
TodayJul 2026
First PostedJun 7, 2007
Enrollment StartJul 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 19.1 years ago
Interventions
Ketorolac tromethaminedrug
31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
Placebodrug
Intranasal (IN) placebo